Related Experiment Videos
Aucte intermittent porphyria and epilepsy.
Archives of Disease in Childhood
|August 1, 1979
Summary
This case study shows that stopping phenobarbitone and phenytoin can treat acute hepatic porphyria. Sodium valproate effectively reduced seizure frequency and severity in a patient with Lennox-Gastaut syndrome.
Area of Science:
- Neurology
- Metabolic Disorders
- Pharmacology
Background:
- Acute hepatic porphyria is a rare metabolic disorder.
- Lennox-Gastaut syndrome is a severe form of epilepsy characterized by myoclonic convulsions and intellectual disability.
- Phenobarbitone and phenytoin are common antiepileptic drugs that can precipitate porphyria attacks.
Observation:
- A 14-year-old boy presented with a history of intermittent acute hepatic porphyria, myoclonic convulsions, and mental retardation consistent with Lennox-Gastaut syndrome.
- The patient's porphyria symptoms were exacerbated by phenobarbitone and phenytoin treatment.
Findings:
- Discontinuation of phenobarbitone and phenytoin led to the resolution of acute hepatic porphyria.
- Administration of sodium valproate at 70 mg/kg/day significantly decreased the frequency and severity of convulsive crises.
Implications:
- This case highlights the critical need to identify and withdraw porphyrogenic medications in patients with epilepsy and a history of porphyria.
- Sodium valproate appears to be a safe and effective alternative antiepileptic drug for managing seizures in patients with Lennox-Gastaut syndrome and a predisposition to porphyria.
- Further research is warranted to explore the long-term efficacy and safety of sodium valproate in this specific patient population.